Argenx Se ADR (ARGX)

Apr 11, 2025, 5:41 PM EDT - 14 days ago

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

Apr 11, 2025, 4:01 PM EDT - 14 days ago

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Apr 10, 2025, 5:59 PM EDT - 15 days ago

US FDA approves syringe version of Argenx's immune disorder drug

Apr 10, 2025, 5:47 PM EDT - 15 days ago

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 8, 2025, 1:00 AM EDT - 18 days ago

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Apr 4, 2025, 2:30 PM EDT - 21 days ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI CCL CEPU CF CROX CUK DECK

Mar 7, 2025, 1:00 AM EST - 7 weeks ago

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Feb 27, 2025, 3:17 PM EST - 2 months ago

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:58 AM EST - 2 months ago

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27, 2025, 1:00 AM EST - 2 months ago

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

Feb 25, 2025, 1:00 AM EST - 2 months ago

argenx to Present at TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 1:00 AM EST - 2 months ago

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Jan 13, 2025, 1:00 AM EST - 3 months ago

argenx Highlights 2025 Strategic Priorities

Jan 6, 2025, 1:00 AM EST - 3 months ago

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 1:00 AM EST - 4 months ago

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Nov 26, 2024, 1:00 AM EST - 5 months ago

argenx to Present at Upcoming Investor Conferences

Nov 20, 2024, 1:00 AM EST - 5 months ago

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Nov 19, 2024, 9:10 AM EST - 5 months ago

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

Nov 11, 2024, 7:30 AM EST - 5 months ago

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Nov 11, 2024, 7:30 AM EST - 5 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ZLAB

Nov 5, 2024, 1:00 AM EST - 6 months ago

argenx to Participate at Upcoming Investor Conferences

Oct 31, 2024, 1:29 PM EDT - 6 months ago

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31, 2024, 1:08 PM EDT - 6 months ago

argenx SE (ARGX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:00 AM EDT - 6 months ago

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 24, 2024, 1:00 AM EDT - 6 months ago

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

Oct 15, 2024, 1:00 AM EDT - 6 months ago

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Sep 24, 2024, 9:06 PM EDT - 7 months ago

argenx: Myositis Data Could Add Billions In Value

Sep 19, 2024, 1:00 AM EDT - 7 months ago

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Aug 12, 2024, 5:13 PM EDT - 9 months ago

Biotech stocks: Which drugmakers are worth a buy?

NVCR

Jul 25, 2024, 1:00 AM EDT - 9 months ago

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

Jul 18, 2024, 1:00 AM EDT - 10 months ago

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

Jul 16, 2024, 12:30 AM EDT - 10 months ago

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Jul 16, 2024, 12:15 AM EDT - 10 months ago

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

ZLAB

Jun 28, 2024, 10:20 AM EDT - 10 months ago

Argenx: Strong Setup For Outperformance In 2025

Jun 25, 2024, 4:30 PM EDT - 10 months ago

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

Jun 24, 2024, 12:43 PM EDT - 10 months ago

Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

Jun 21, 2024, 4:50 PM EDT - 11 months ago

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 17, 2024, 1:00 AM EDT - 11 months ago

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024

Jun 4, 2024, 1:00 AM EDT - 11 months ago

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 9, 2024, 4:39 PM EDT - 1 year ago

argenx SE (ARGX) Q1 2024 Earnings Call Transcript

May 9, 2024, 1:00 AM EDT - 1 year ago

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 5:30 PM EDT - 1 year ago

argenx announces results of Annual General Meeting of Shareholders

May 7, 2024, 4:02 AM EDT - 1 year ago

argenx: Innovation Over Losses In Autoimmune Arena

May 7, 2024, 1:00 AM EDT - 1 year ago

argenx to Present at BofA Securities 2024 Health Care Conference

May 2, 2024, 1:00 AM EDT - 1 year ago

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

Apr 16, 2024, 1:00 AM EDT - 1 year ago

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Mar 27, 2024, 2:00 AM EDT - 1 year ago

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Mar 26, 2024, 4:00 PM EDT - 1 year ago

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

Mar 26, 2024, 2:00 AM EDT - 1 year ago

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Mar 7, 2024, 4:01 PM EST - 1 year ago

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting